サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795172

トゥレット症候群治療薬の世界市場

Tourettes Syndrome Drugs

出版日
ページ情報
英文 274 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
トゥレット症候群治療薬の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トゥレット症候群治療薬の世界市場は2030年までに27億米ドルに達する見込み

2024年に20億米ドルと推定されるトゥレット症候群治療薬の世界市場は、分析期間2024-2030年にCAGR 5.2％で成長し、2030年には27億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗精神病性トゥレット症候群治療薬は、CAGR 4.1%を記録し、分析期間終了時には15億米ドルに達すると予測されます。非抗精神病性トゥレット症候群治療薬セグメントの成長率は、分析期間中CAGR 6.8%と推定されます。

米国市場は推定5億3,770万米ドル、中国はCAGR 8.1％で成長予測

米国のトゥレット症候群治療薬市場は2024年に5億3,770万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.1％をたどり、2030年までに5億2,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.1%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界のトゥレット症候群治療薬市場- 主要動向と促進要因まとめ

トゥレット症候群の医薬品開発が勢いを増す理由とは？

トゥレット症候群（TS）は、不随意的な運動や発声のチックを特徴とする神経発達障害であり、これまで標的を絞った効果的な薬理学的介入は行われてきませんでした。ほとんどの治療は抗精神病薬や覚せい剤の適応外使用に頼っており、副作用も大きく、有効性も限られていました。しかし、認知度の向上と診断の明確化により、単なる症状抑制ではなく、その根底にある神経学的メカニズムに対処する、より個別化された治療法の研究が推進されつつあります。

最近の神経薬理学と脳画像診断の動向は、ドーパミンとグルタミン酸の経路をより正確に調節する薬剤の開発に新たな道を開いています。いくつかの後期臨床試験では、非ドパミン作動性薬剤、カンナビノイドベースの治療薬、さらには一部のTS症例で観察される神経炎症性要素に対処するための免疫調節薬に焦点が当てられています。有効性と最小限の副作用のバランスが取れた薬剤の追求は、特に治療耐性が大きな懸念事項である小児集団にとって、現在優先事項となっています。

バイオテクノロジーの革新と小児科の承認は、治療情勢をどのように変えているのか？

希少疾病用医薬品（オーファンドラッグ）指定と迅速承認が登場したことで、TS療法の開発パイプラインは加速しています。バイオテクノロジー企業は、遺伝子や神経免疫の標的を探索し、有望な初期結果を得ています。さらに、デジタルバイオマーカーとAIを活用した臨床試験プラットフォームの統合により、エンドポイント測定と患者層別化が改善され、臨床試験がより効率的かつ適切なものとなっています。

小児用の製剤開発と早期段階の研究に小児を含めることで、年齢相応で忍容性の高い治療薬へのアクセスも拡大しています。認知行動療法（CBT）や習慣逆転トレーニングの効果を薬物療法で高める、行動薬理学的併用治療への関心が高まっています。その結果、トゥレット症候群の治療において、より微妙で多様な治療法が確立されつつあります。

トゥレット症候群治療薬市場の成長はいくつかの要因によって牽引されている...

市場は、特に小児集団における診断率の上昇と、TSが明確な神経学的疾患であるという認識の高まりによって成長しています。ドーパミン、セロトニン、グルタミン酸受容体を標的とした神経薬理学の進歩により、新たな治療選択肢が生まれつつあります。オーファンドラッグ（希少疾病用医薬品）ステータスやファストトラック指定などの規制上の優遇措置が臨床開発を後押ししています。カンナビノイドや免疫療法の研究開発活動が拡大し、治療の幅が広がっています。さらに、臨床試験や患者モニタリングにおけるデジタル統合と相まって、より忍容性が高く年齢に適した製剤への需要が、この特殊な市場における技術革新と商業的関心を促進しています。

セグメント

製品展望（抗精神病性トゥレット障害、非抗精神病性トゥレット障害）、流通チャネル（オフライン、オンライン）

調査対象企業の例

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Catalyst Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Emalex Biosciences Inc.
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals（J&J）
  • Mitsubishi Tanabe Pharma Corp.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Reviva Pharmaceuticals Inc.
  • Sanofi S.A.
  • SciSparc Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38228

Global Tourettes Syndrome Drugs Market to Reach US$2.7 Billion by 2030

The global market for Tourettes Syndrome Drugs estimated at US$2.0 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Antipsychotic Tourette's Syndrome Drugs, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Antipsychotic Tourette's Syndrome Drugs segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$537.7 Million While China is Forecast to Grow at 8.1% CAGR

The Tourettes Syndrome Drugs market in the U.S. is estimated at US$537.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$528.7 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Tourettes Syndrome Drugs Market - Key Trends & Drivers Summarized

Why Is Drug Development for Tourette’s Syndrome Gaining Momentum?

Tourette’s Syndrome (TS), a neurodevelopmental disorder characterized by involuntary motor and vocal tics, has historically lacked targeted and effective pharmacological interventions. Most treatments relied on off-label use of antipsychotics or stimulants, with significant side effects and limited efficacy. However, growing awareness and improved diagnostic clarity are driving research into more tailored therapies that address the underlying neurological mechanisms rather than just symptom suppression.

Recent advancements in neuropharmacology and brain imaging have opened new avenues for developing drugs that modulate dopamine and glutamate pathways more precisely. Several late-stage clinical trials are focusing on non-dopaminergic agents, cannabinoid-based therapies, and even immunomodulators to address the neuroinflammatory component observed in some TS cases. The pursuit of drugs that balance efficacy with minimal side effects is now a priority, especially for pediatric populations where treatment tolerance is a major concern.

How Are Biotech Innovations and Pediatric Approvals Transforming the Therapeutic Landscape?

The emergence of orphan drug designations and fast-track approvals is accelerating the development pipeline for TS therapies. Biotech firms are exploring genetic and neuroimmune targets with promising early results. Moreover, the integration of digital biomarkers and AI-powered trial platforms is improving endpoint measurement and patient stratification, making clinical trials more efficient and relevant.

Pediatric formulation development and the inclusion of children in early-stage research are also expanding access to therapies that are age-appropriate and better tolerated. There is increasing interest in behavioral-pharmacological combination treatments, where medication is used to enhance the efficacy of cognitive behavioral therapy (CBT) and habit reversal training. As a result, a more nuanced and multi-modal treatment ecosystem is beginning to take shape for Tourette’s Syndrome.

The Growth in the Tourettes Syndrome Drugs Market is Driven by Several Factors…

The market is growing due to rising diagnosis rates, especially in pediatric populations, and increasing awareness of TS as a distinct neurological condition. Advances in neuropharmacology targeting dopamine, serotonin, and glutamate receptors are creating new therapeutic options. Regulatory incentives like orphan drug status and fast-track designations are supporting clinical development. Expanding R&D activity in cannabinoids and immunotherapies is broadening treatment scope. Additionally, demand for better-tolerated and age-appropriate formulations, coupled with digital integration in clinical trials and patient monitoring, is fueling innovation and commercial interest in this specialized market.

SCOPE OF STUDY:

The report analyzes the Tourettes Syndrome Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Outlook (Antipsychotic Tourette's Syndrome Drugs, Non-Antipsychotic Tourette's Syndrome Drugs); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Catalyst Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Emalex Biosciences Inc.
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals (J&J)
  • Mitsubishi Tanabe Pharma Corp.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Reviva Pharmaceuticals Inc.
  • Sanofi S.A.
  • SciSparc Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tourettes Syndrome Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates and Growing Awareness Fuel Demand for Tourettes Syndrome Treatment
    • Increased Prescription of Antipsychotics and Alpha-Agonists Supports Market Growth
    • Development of Next-Generation Dopamine Modulators Drives Innovation Pipeline
    • Growing Use of Off-Label Therapies in Pediatric Neuropsychiatric Care Expands Treatment Base
    • Demand for Improved Safety Profiles Spurs Research in Non-Sedating Therapeutic Alternatives
    • Increased Interest in Behavioral Pharmacotherapy Combinations Enhances Care Outcomes
    • Expansion of Clinical Trials for Novel CNS Agents Strengthens Regulatory Momentum
    • Focus on Tics and Comorbidity-Specific Drug Approvals Broadens Treatment Precision
    • Improved Insurance Coverage and Access to Specialized Clinics Supports Medication Uptake
    • Rising Demand for Long-Acting and Extended-Release Formulations Improves Compliance
    • Adoption of Central Nervous System Biomarkers Enhances Targeted Drug Development
    • Use of Digital Therapeutics Alongside Pharmacological Regimens Supports Integrated Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tourettes Syndrome Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tourettes Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tourettes Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antipsychotic Tourette's Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antipsychotic Tourette's Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antipsychotic Tourette's Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Antipsychotic Tourette's Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Antipsychotic Tourette's Syndrome Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Antipsychotic Tourette's Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Tourettes Syndrome Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Tourettes Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Tourettes Syndrome Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Tourettes Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Tourettes Syndrome Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Tourettes Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Tourettes Syndrome Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Tourettes Syndrome Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Tourettes Syndrome Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Tourettes Syndrome Drugs by Product Outlook - Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Tourettes Syndrome Drugs by Product Outlook - Percentage Breakdown of Value Sales for Antipsychotic Tourette's Syndrome Drugs and Non-Antipsychotic Tourette's Syndrome Drugs for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Tourettes Syndrome Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Tourettes Syndrome Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION